Past oral contraceptive and hormone therapy use and endogenous hormone concentrations in postmenopausal women

Menopause

Volumn 15, Issue 2, 2008, Pages 332-339

  Chan, Mei Fen ^a   Dowsett, Mitch ^b   Folkerd, Elizabeth ^b   Wareham, Nicholas ^c   Luben, Robert ^a   Welch, Ailsa ^a   Bingham, Sheila ^d   Khaw, Kay Tee ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Estradiol; Hormone therapy; Oral contraceptives; Sex hormones; Testosterone

Indexed keywords

ANDROSTENEDIONE; ESTRADIOL; ESTRONE; HYDROXYPROGESTERONE; ORAL CONTRACEPTIVE AGENT; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; AGED; ARTICLE; BODY MASS; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HEALTH HAZARD; HORMONAL THERAPY; HORMONE BLOOD LEVEL; HUMAN; HYSTERECTOMY; MENARCHE; ORAL CONTRACEPTION; PHYSICAL ACTIVITY; POSTMENOPAUSE; RADIOIMMUNOASSAY; SMOKING HABIT;

AGED; AGED, 80 AND OVER; ANDROSTENEDIONE; CONTRACEPTIVES, ORAL; CROSS-SECTIONAL STUDIES; DRUG ADMINISTRATION SCHEDULE; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTRONE; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TIME;

EID: 40449132763     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e31806458d9     Document Type: Article

References (50)

1. Tazuke S, Khaw KT, Barrett-Connor E. Exogenous estrogen and endogenous sex hormones. Medicine 1992;71:44-51.
2. Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal human cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:767-770.
3. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 2002;94:606-616.
4. Zeleniuch-Jacquotte A, Shore RE, Koenig KL, et al. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study. Br J Cancer 2004;90:153-159.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies. Lancet 1996;347:1713-1727.
6. Marchbanks PA, McDonald JA, Wilson HG. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002;346:2025-2032.
7. Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer 2003;105:844-850.
8. Beral V, Banks E, Reeves G. Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet 2002;360:924-944.
9. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in health postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
10. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-1712.
11. Stahlberg C, Pederson AT, Lynge E, Otteson B. Hormone replacement therapy and risk of breast cancer: the role of progestins. Acta Obstet Gynecol Scand 2003;82:335-344.
12. Day N, Oakes S, Luben R, et al. EPIC-Norfolk: study design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer 1999;80(Suppl 1):95-103.
13. Dunning AM, Dowsett M, Healey CS, et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J Natl Cancer Inst 2004;96:936-945.
14. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997;26(Suppl 1):S6-S14.
15. Wareham NJ, Jakes RW, Rennie KL, Mitchell J, Hennings S, Day NE. Validity and repeatability of the EPIC-Norfolk Physical Activity Questionnaire. Int J Epidemiol 2002;31:168-174.
16. Wiegratz I, Kutschera E, Lee JH, Mellinger U, Winkler UH, Kuhl H. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003;67:25-32.
17. Isaksson E, von Schoultz E, Odlind V, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001;65:163-169.
18. Aden U, Jung-Hoffman C, Kuhl H. A randomized cross-over study on various hormonal parameters of two triphasic oral contraceptives. Contraception 1998;58:75-81.
19. Fern M, Rose DP, Fern EB. Effect of oral contraceptives on plasma androgenic steroids and their precursors. Obstet Gynaecol 1978;51:541-544.
20. Hemrika DJ, Slaats EH, Shoemaker J. The response of the pituitary-ovarian axis to pulsatile administration of gonadotropin-releasing hormone in long-term oral contraceptive users. Am J Obstet Gynecol 1994;170:462-468.
21. Jung-Hoffmann C, Kuhl H. Divergent effects of two low-dose oral contraceptives on sex hormone-binding globulin and free testosterone. Am J Obstet Gynecol 2004;156:199-203.
22. Refn HL, Kjaer A, Lebech AM, Borggaard B, Schierup L. Clinical and hormonal effects of two contraceptives: correlation to serum concentrations of levonorgestrel and gestodene. Contraception 1990;41:259-269.
23. Coenen CMH, Thomas CMG, Borm GF, Hollanders JMG, Rolland R. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996;53:171-176.
24. Kuhnz W, Staks T, Jutting G. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. Contraception 1994;59:563-579.
25. Kuhnz W, Baumann A, Staks T, Dibbelt L, Knuppen R, Jutting G. Pharmacokinetics of gestodene and ethinylestradiol in 14 women during three months of treatment with a new tri-step combination oral contraceptive: serum protein binding of gestodene and influence of treatment on free and total testosterone levels in the serum. Contraception 1993;48:303-322.
26. Kim-Bjorklund T, Landgren BM, Hamberger L. Is the contraceptive effect of 300 micrograms of norethisterone mainly peripheral or central? Contraception 1992;45:57-66.
27. Madden JD, Milewich L, Parker CR, Carr BR, Boyar RM, MacDonald PC. The effect of oral contraceptive treatment on the serum concentration of dehydroisoandrosterone sulfate. Am J Obstet Gynecol 1978;132:380-384.
28. Gaspard UJ, Romus MA, Gillain D, Duvivier J, Demey-Ponsart E, Franchimont P. Plasma hormone levels in women receiving new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception 1983;27:577-590.
29. Gaspard UJ, Dubois M, Gillain D, Franchimont P, Duvivier J. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Contraception 1984;29:305-318.
30. van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA. Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception 1990;41:345-352.
31. Rose DP, Fern M, Liskowski L, Milbrath JR. Effect of treatment with estrogen conjugates on endogenous plasma steroids. Obstet Gynecol 1977;49:80-82.
32. Veldhuis JD, Samojlik E, Evans WS, et al. Endocrine impact of pure estradiol replacement in postmenopausal women: alterations in anterior pituitary hormone release and circulating sex steroid hormone concentrations. Am J Obstet Gynecol 1986;155:334-339.
33. Helgason S, Carlstrom K, Damber MG, Damber JE, Selstram G, von Schoultz B. Effects of various oestrogens on circulating androgens and cortisol during replacement therapy in post-menopausal women. Maturitas 1981;3:301-308.
34. Casson PR, Elkind-Hirsch KE, Buster JE, Hornsby PJ, Carson SA, Snabes MC. Effect of postmenopausal estrogen replacement on circulating androgens. Obstet Gynecol 1997;90:995-998.
35. Kraemer GR, Kraemer RR, Ogden BW, Kilpatrick RE, Gimpel TL, Castracane D. Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin. Fertil Steril 2003;79:534-542.
36. Slater CC, Zhang C, Hpdis HN, et al. Comparison of estrogen and androgen levels after oral estrogen replacement therapy. J Reprod Med 2001;46:1052-1056.
37. Geola FL, Frumar AM, Tataryn IV, et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1980;51:620-625.
38. Cappola AR, Ratcliffe SJ, Bhasin S, et al. Determinants of serum total and free testosterone levels in women over the age of 65 years. J Clin Endocrinol Metab 2007;92:509-516.
39. Nugent AG, Leung KC, Sullivan D, Reutens AT, Ho KK. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Clin Endocrinol 2003;59:690-698.
40. Hellman L, Yoshida K, Zumoff B, Levin J, Kraem J, Fukushima DK. The effect of medroxyprogesterone acetate on the pituitary-adrenal axis. J Clin Endocrinol Metab 1976;42:912-917.
41. Odell WD, Parker LN. Control of adrenal androgen production. Endocr Res 1984;10:617-630.
42. Norell SE, Boethius G, Persson I. Oral contraceptive use: interview data versus pharmacy records. Int J Epidemiol 2005;27:1033-1037.
43. Bernstein L, Ross RK. Endogenous hormones and breast cancer. Epidemiol Rev 1993;15:48-65.
44. Hankinson SE, Manson JE, Spiegelman D, Willett WC, Longcope C. Reproducibility of plasma hormone levels in postmenopausal women over a 2-3-year period. Cancer Epidemiol Biomarker Prev 1995;4:649-654.
45. Toniolo P, Koenig KL, Pasternack BS, Banerjee S, Rosenberg C, Shore RE. Reliability of measurements of total, protein-bound, and unbound estradiol in serum. Cancer Epidemiol Biomarker Prev 1994;3:47-50.
46. Michels KB, Willett WC. Breast cancer - early life matters. N Engl J Med 2004;351:1679-1681.
47. Ahlgren M, Melbye M, Wohlfahrt J, Sorenson TI. Growth patterns and the risk of breast cancer in women. N Engl J Med 2004;351:1619-1626.
48. Elias SG, Onland-Moret NC, Peeters PH, et al. Urinary endogenous sex hormone levels in postmenopausal women after caloric restriction in young adulthood. Br J Cancer 2004;90:115-117.
49. Tworoger SS, Hankinson SE. Prolactin and breast cancer risk. Cancer Lett 2006;243:160-169.
50. Somboonporn W, Davis SR. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev 2004;25:374-388.